Pitkin Joan, Rees Margaret C P, Gray Sarah, Lumsden Mary Ann, Stevenson John, Williamson Jennifer
Menopause Clinical & Research Unit, Division of Women & Children Norhwick Park & St Marks Hospital Watford Road, Harrow, Middlesex, UK.
J Br Menopause Soc. 2003 Sep;9(3):129-31. doi: 10.1258/136218003100322260.
The British Menopause Society Council aims to aid health professionals to inform and advise women about the menopause. The oestrogen plus progestogen arm of the Women's Health Initiative was stopped in July 2002. This guidance regarding hormone replacement therapy (HRT) use responds to the results and analysis that have been published since then. Because there are few effective alternatives to HRT for vasomotor and urogenital symptoms, oestrogen-based treatments still have a major role. HRT is also most effective for prevention of osteoporosis. Unopposed oestrogens are contraindicated in women with an intact uterus, and hence a range of oestrogen and progestogen combinations, with differing routes of delivery, now exists under the title of "HRT". Treatment choice should be based on up to date information and targeted to individual women's needs. Hormone replacement still offers the potential for benefit to outweigh harm, providing the appropriate regimen has been instigated in terms of dose, route and combination.
英国更年期协会理事会旨在帮助健康专业人员为女性提供有关更年期的信息并给予建议。妇女健康倡议（Women's Health Initiative）的雌激素加孕激素组于2002年7月停止。本关于激素替代疗法（HRT）使用的指南是对自那时以来已发表的结果和分析做出的回应。由于对于血管舒缩症状和泌尿生殖系统症状而言，HRT几乎没有有效的替代方法，基于雌激素的治疗仍然发挥着主要作用。HRT对于预防骨质疏松症也最为有效。对于子宫完整的女性，不使用孕激素的雌激素是禁忌的，因此现在有一系列不同给药途径的雌激素和孕激素组合，统称为“激素替代疗法（HRT）”。治疗选择应基于最新信息，并针对个别女性的需求。如果在剂量、途径和组合方面采用了适当的方案，激素替代疗法仍有可能使益处大于危害。
